COMPANY
Iantrek
Iantrek develops micro-interventional instruments and implants for glaucoma surgery, including the AlloFlo Uveo and its Allosert Uveo delivery system. From company website Source · Oct 12, 2026
Timeline
- Raise Private equity round — Series C: $42M (total, as published), announced Aug 20, 2025. Source: company release on GlobeNewswire. source ↗
Funding
- Private equity round — Series C: $42M (total, as published), announced Aug 20, 2025. Source: company release on GlobeNewswire. source ↗